硫尼尔化衍生物向谷氨降解酶:在癌症中进行氧化调节的潜在策略
Erbay Kalay1, Halide Sedef Karaman2, Osman Nuri Aslan3
1Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Turkey.
Chemical biology & drug design
|November 5, 2025
概括
新的硫尼尔化类型被合成并测试为谷氨缩酶 (GR) 抑制剂,一种在瘤中过度表达的酶. 化合物6a显示强大的GR抑制和抗癌活性,表明作为候选药物的潜力.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 氨酸减少酶 (GR) 对于维持细胞氧化还原平衡至关重要,并且在癌细胞中经常过度表达.
- 这种过度表达通过中和活性氧物种并维持抗氧化防御来支持瘤细胞的生存.
研究的目的:
- 合成和评估新型硫尼尔化类似物作为人类谷氨还原酶 (hGR) 的潜在抑制剂.
- 为了研究已知的最强效抑制剂的作用机制和抗癌潜力.
主要方法:
- 硫尼尔化类型的合成和表征.
- 在体外酶抑制试验测试以确定IC50值.
- 在基分子对接研究中,以阐明结合相互作用.
- 在体外细胞毒性测定对人类癌细胞系 (MCF-7,A549,HeLa).
主要成果:
- 一系列的化合物被合成,hGR抑制的IC50值从198.1到3013nm不等.
- 化合物6a表现出最强大的hGR抑制.
- 在分析显示,化合物6a与hGR的NADP+结合部位结合,干扰电子转移.
- 化合物6a对MCF-7,A549和HeLa细胞表现出细胞毒性作用,EC50值在微分子到毫米分子范围内.
- 化合物6a在毫米克度下显示出弱细胞毒性,特别针对MCF-7细胞.
结论:
- 硫尼尔化类似物是hGR的有效抑制剂.
- 化合物6a是一种强大的hGR抑制剂,具有已证明的抗癌活性.
- 提高化合物6a的膜透性可以提高其作为抗癌药物候选药物的治疗潜力.
相关概念视频
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Sulfur Assimilation
314
Sulfur is an essential element in biological systems, contributing to synthesizing key biomolecules, including amino acids such as cysteine and methionine, and cofactors such as coenzyme A and biotin. Microorganisms primarily assimilate sulfur as sulfate (SO₄²⁻) from the environment, which must undergo a series of biochemical transformations before it can be incorporated into cellular components. As sulfate is highly oxidized, it must undergo assimilatory sulfate reduction to...
314
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
803
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
803
Drug Metabolism: Phase II Reactions
4.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.8K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Oral Hypoglycemic Agents: Sulfonylureas
752
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
752


